Small Cap Feast

Small Cap Feast – 20 January 2020

Set Menu AIM:

Total number of AIM Companies (Incl Susp):

Total number of AIM Companies trading: *
* As at

Set Menu NEX Growth:

Total number of NEX Growth Market Companies (Incl Susp): *

Total number of NEX Growth Market Companies trading: *
* As at

Set Menu Standard List:

Total number of Standard List Companies (Incl Susp): *

Total number of Standard List Companies trading: *
* As at

Dish of the Day:

No Joiners Today


Off the Menu:

Hvivo has left AIM after being acquired by Open Orphan, Techfinancials has left AIM, remains on NEX,  Cobham has left the Main Market (premium) following an acquisition, RM2 has left AIM pursuant to rule 41, Aggregated Micro Power has left AIM following an acquisition.


Dish of the Day:

Off the Menu:

What’s Cooking in the IPO Kitchen?


Intention to float by Gemfields Group. No Capital Raise. Currently listed on JSE. (GML:JNB) at circa £122m.  The Group’s key producing assets, the Kagem emerald mine in Zambia  (believed to be the world’s single largest producing emerald mine) and the Montepuez ruby mine in Mozambique (one of the most significant recently discovered ruby deposits in the world), are both expected to have long mine-lives with potential for expansion. Also owns the  Faberge brand. Due Valentines Day 2020.

Main Market (Standard List)

The Proof Of Trust has announced its intention to list on the Standard Market.  The Blockchain based business, owns patents to a protocol which facilitates dispute resolution based upon smart contract disputes.  Transaction details TBC.

Main Market (Premium)

Calisen Group. Potential Intention to Float. Owner and manager of essential energy infrastructure assets through its subsidiaries Calvin Capital and Lowri Beck . Consolidated FY Dec 18 revenue £162.1m and operating profit £25.4m. Raising up to £300m in primary plus partial vendor sale.  Expected Admission February 2020

The Global Sustainable Farmland Income Trust will invest in a diversified portfolio of operational farmland assets located in major agricultural markets including the United States, Europe, New Zealand, Australia and certain countries within Latin and South America. Raising up to $300m.   Due 28 February.

Main Market (Specialist Funds)

Investment firm Nippon Active Value fund is seeking to raise up to £200m at an issue price of 100p per share via an IPO.   The company aims to invest in a portfolio of quoted Japanese stocks with market capitalisations of up to $1bn.   First day of dealings expected early February.


Breakfast Buffet

Tribal Group (TRB.L) 73p £144m

The provider of software and services to the international education market, announced the appointment of Nigel Halkes as Non-Executive Director with effect from 20th January 2020 and Chair of the Audit Committee following the AGM in May 2020.

Nigel is a Fellow of the Institute of Chartered Accountants, qualifying with EY. He spent 35 years at EY and retired as Managing Partner, UK and Ireland Markets in 2013. During his three-year leadership, EY was the fastest growing of the ‘Big 4’ in the UK and Ireland. Between 1995 and 2003 Nigel was EY’s National Industry Leader for Technology, Media & Telecoms.


MaxCyte (MXCT.L) 132p £67.8m

 The global clinical-stage cell-based therapies and life sciences company, provided a trading update for the year ended 31 December 2019.

  • Revenue exceeds market expectations
  • Five new gene-editing cell therapy deals signed in 2019; eight clinical and commercial cell therapy deals now in total; potential pre-commercial milestones in excess of $650m
  • Launch of ExPERTTM technology supporting high demand for instruments and disposables
  • Lead wholly-owned drug development programme progressing through Phase I clinical trial
  • CARMA subsidiary established and seeking investors and new partnerships for CARMA™ platform


Rockfire Resources (ROCK.L) 1p £6.3m

Drilling has commenced to expand gold mineralisation encountered in hole BPL025, at the Company’s 100%-owned Plateau Gold Deposit in Queensland, Australia. As announced on 26 November 2019, hole BPL025 intersected 177 m @ 0.5 g/t Au.

  • Reverse Circulation (RC) drilling now in progress, with a planned program of 1,500 m of drilling in 13 proposed drill holes
  • The drill program has two objectives:

o  Exploration at depths of around 250 m below surface

o  Extension and infilling of near-surface resources (< 80 m deep)

  • Geophysical anomaly to be tested by drilling two holes, 50 m and 150 m respectively, east of hole BPL025
  • The drill program is expected to take approximately 15 days to complete, with gold analyses to follow the completion of drilling.


Ergomed (ERGO.L) 427p £202m

The a company focused on providing specialised services to the pharmaceutical industry, announced the appointment of Lewis Cameron as Chief Operating Officer (COO) and to the Board. Ergomed confirms that, as stated in that announcement, Lewis has today commenced his employment as COO and his appointment to the Board has been effected.   

Ergomed confirms that there have been no changes to the disclosures made in the announcement dated 2 December 2019 (RNS number 2883V) regarding Rule 17 of paragraph (g) of Schedule Two of the AIM Rules for Companies in respect of Lewis Cameron’s appointment.


TMT Investments* TMT (TMT.L) 414c $120.8m

Portfolio Update since 17 Sep 19.

Positive revaluations

Le Tote.  In November 2019, online fashion rental start-up Le Tote acquired Lord & Taylor, the US’s oldest department store.  The transaction resulted in an increase of approximately US$0.75m in the value of TMT’s interest in Le Tote.  Platform as a Service (PaaS) provider of enterprise-class networking services has recently completed an equity financing round.  The transaction resulted in an increase of approximately US$2.2m in the value of TMT’s interest in

 Negative revaluations

Sixa.  Full impairment of US$0.9m.   Drupe.  Full impairment of US$0.6m.

Nearly $2m of new investments, in performance marketing, advertising monitoring, and mobile software for the timber industry.

The combined effect of these revaluations represents approximately 5c per TMT share (before adjustments ). “We expect a number of further positive revaluations across our portfolio in 2020 and will update shareholders on relevant developments as appropriate.  With a continued strong cash balance, we continue to apply our highly selective criteria to identify new promising investment opportunities.”



Notes the press report over the weekend regarding a possible transaction between the Company and  Ptarmigan SA.

The Board confirms that it is in preliminary discussions regarding the possible acquisition of Ptarmigan SA by the Company. Should such a transaction proceed on the currently envisaged terms, it would be classified as a reverse takeover in accordance with the AIM Rules for Companies. Accordingly, the Company’s shares are suspended from trading on AIM with immediate effect and will remain so until either the publication of an admission document setting out, inter alia, details of the proposed transaction or until confirmation is given that these discussions have ceased.

Ptarmigan is a health and leisure resort development company based in the valley of Evolene, in the Canton of Valais, Switzerland and is owned by the Truell family, a 25% shareholder of Sabien.

Shareholders should note that the proposed acquisition is at an early stage of discussion and subject to a number of pre-conditions and due diligence, and there can be no certainty therefore at this time that the acquisition will proceed as envisaged.


Touchstone Exploration(TXP.L) 22p £35.4m

Exploration update, highlighted by the first stage of production testing of the Cascadura-1ST1 well on the Ortoire exploration block, onshore in the Republic of Trinidad and Tobago. The Cascadura-1ST1 production test was designed to evaluate a potential oil zone as indicated by cased hole logs. On commencement of testing, significant pressures and natural gas volumes were encountered on the clean-up flow. As a result, the Company suspended testing to bring in the appropriate equipment to measure high volumes of both natural gas and liquids.

“This is the best possible outcome for the initial test results from the Cascadura well, as natural gas and liquids have superior economic value under the Trinidad fiscal regime”.


Kape Technologies (KAPE.L) 168p £262m

FY Dec 19 update from the digital security and privacy software business .

The acquisition of PIA will be significantly earnings enhancing for Kape, and further bolsters the Group’s SaaS operating model. Kape’s user base grew to 2.35m subscribers at year-end (30 June 2019: 1m), comprising 74.3% organic growth within the privacy vertical not including PIA. Kape expects to deliver $98.8m in revenues from existing customers in future financial years, up 260% (30 June 2019: $38.0m).

Kape traded strongly throughout 2019 with a focus on profitable growth. Adjusted EBITDA is expected to be slightly above market expectations at c.$14.5m (2018: $10.4m), representing an increase of 40%, with revenues up 26% to c.$66.0m. At the time of the PIA acquisition, the Group issued guidance for the year ending 31 December 2020, with revenues expected to be in the range of $120m to $123m and Adjusted EBITDA between $35m and $38m.


Inspiration Health (IHC.L) 67.5p £25.7m

The global medical technology company, has received an order from the Ministry of Health of Sri Lanka for the supply of 15 HIE Workstations, used for diagnosing and treating Hypoxic-Ischaemic Encephalopathy in the new-born.   its receipt does not alter the financial expectations of the company for the current year which remain in line with current forecasts.

M&C Saatchi (SAA.L) 117.5p £109m

 FYDec19 update. The Company anticipates that underlying PBT , will be in line with the Board’s expectations as set out in the trading update of 4 December 2019. Also expects net cash to be at least £15m, substantially ahead of expectations following the implementation of improved cash collection processes.


Head Chef:

Derren Nathan
0203 764 2344

*A corporate client of Hybridan LLP


This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.

The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.

The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).

Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.

This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.

In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.

Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.

Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.

Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.

This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.

MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.

Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.

If you would like to unsubscribe, please email with “unsubscribe me”.